{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:59:27Z","timestamp":1792807167633,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Ataxia telangiectasia and Rad3-related kinase (ATR) is a central regulator of the DNA damage response and a promising therapeutic target in tumors with genomic instability. This meta-analysis evaluated the efficacy and safety of ATR inhibitors in patients with solid tumors. A systematic search of PubMed, Embase, and major Chinese and international databases up to September 2025 identified ten clinical trials including 810 patients treated with ATR inhibitors as monotherapy or in combination. Outcomes assessed included objective response rate, disease control rate, progression-free survival, overall survival, and treatment-related adverse events. Pooled analyses showed no significant overall improvement in efficacy endpoints compared with standard therapies. However, subgroup analysis demonstrated marked benefit in non-small cell lung cancer, with significantly prolonged progression-free survival and overall survival, while efficacy in other tumor types was minimal. The overall risk of adverse events was comparable to control groups, although hematologic toxicities such as myelosuppression (pooled RR = 1.04) and neutropenia (pooled RR = 1.34) were common. These findings suggest that ATR inhibitors may be particularly effective in non-small cell lung cancer and selected ovarian cancer subgroups, but further biomarker-driven randomized trials are required to confirm their clinical value and optimize patient selection.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251123612.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1706837","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:14:24Z","timestamp":1764652464000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy and safety of ATR inhibitors in the treatment of solid tumors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yaxu","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/1878-0261.13020","article-title":"DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies","volume":"16","author":"Rominiyi","year":"2022","journal-title":"Mol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000745","article-title":"DNA damage response","volume":"3","author":"Giglia-Mari","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1034","article-title":"HERC2-USP20 axis regulates DNA damage checkpoint through claspin","volume":"42","author":"Yuan","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.3390\/molecules27082491","article-title":"Recent advances in synergistic antitumor effects exploited from the inhibition of ataxia telangiectasia and RAD3-related protein kinase (ATR)","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"B5","doi-asserted-by":"publisher","first-page":"431369403","DOI":"10.1177\/1758835920982853","article-title":"ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer","volume":"12","author":"Feng","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13058-020-01289-4","article-title":"Clinical and functional significance of tumor\/stromal ATR expression in breast cancer patients","volume":"22","author":"Al-Ansari","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.581217","article-title":"Predictive and prognostic value of DNA damage response associated kinases in solid tumors","volume":"10","author":"Gachechiladze","year":"2020","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113797","article-title":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","volume":"155","author":"Ahmed","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.3390\/cancers14102561","article-title":"Homologous recombination repair in biliary tract cancers: a prime target for PARP inhibition","volume":"14","author":"Yin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.3390\/molecules28114521","article-title":"Design, synthesis, and biological evaluation of potent and selective inhibitors of ataxia telangiectasia mutated and rad3-related (ATR) kinase for the efficient treatment of cancer","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.10.016","article-title":"ATR inhibition in advanced urothelial carcinoma","volume":"21","author":"Leibrandt","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase i study of ATR inhibitor m6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02404","article-title":"Phase i trial of first-in-class ATR inhibitor m6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0305","article-title":"ATR inhibitor m6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient-derived xenografts","volume":"20","author":"Baschnagel","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-human study of the ataxia telangiectasia and rad3-related (ATR) inhibitor tuvusertib (m1774) as monotherapy in patients with solid tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"a031518","DOI":"10.1101\/cshperspect.a031518","article-title":"Synthetic lethal vulnerabilities in KRAS-mutant cancers","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-chk2 and ATR-chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-l1 cytotoxicity in prostate cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase i study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.06.011","article-title":"KEAP1 and STK11\/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer","volume":"43","author":"Galan-Cobo","year":"2025","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/cancers12051206","article-title":"Exploiting the prevalence of homologous recombination deficiencies in high-grade serous ovarian cancer","volume":"12","author":"Bouberhan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0235766","DOI":"10.1371\/journal.pone.0235766","article-title":"Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene","volume":"15","author":"Mittempergher","year":"2020","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1038\/s41467-025-58183-w","article-title":"Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR","volume":"16","author":"Xu","year":"2025","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2016.05.020","article-title":"ATR-mediated regulation of nuclear and cellular plasticity","volume":"44","author":"Kidiyoor","year":"2016","journal-title":"DNA Repair (Amst)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11684","DOI":"10.3390\/ijms241411684","article-title":"Novel cellular functions of ATR for therapeutic targeting: embryogenesis to tumorigenesis","volume":"24","author":"Biswas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by ATR inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"(ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/jcm8040435","article-title":"PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers","volume":"8","author":"Keung","year":"2019","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2300635","DOI":"10.1200\/PO.23.00635","article-title":"Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival and biomarker analyses","volume":"8","author":"Konstantinopoulos","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4_suppl.614","DOI":"10.1200\/JCO.2024.42.4_suppl.614","article-title":"Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma","volume":"42","author":"Parikh","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35059","article-title":"Biomarker-driven phase 2 umbrella trial: clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer","volume":"130","author":"Park","year":"2024","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S1242","DOI":"10.1016\/j.annonc.2024.08.2293","article-title":"LBA8 precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(l)1 inhibitors resistance (PIONeeR): a phase ib\/IIa clinical trial targeting identified resistance pathways","volume":"35","author":"Tomasini","year":"2024","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4025","article-title":"Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial","volume":"9","author":"Takahashi","year":"2023","journal-title":"JAMA Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.180","article-title":"VIOLETTE: randomised phase II study of olaparib (ola) plus ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)","volume":"33","author":"Tutt","year":"2022","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"15_suppl.5034","DOI":"10.1200\/JCO.2021.39.15_suppl.5034","article-title":"A phase 2 study of berzosertib (m6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer","volume":"39","author":"Choudhury","year":"2021"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3441","article-title":"Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Pal","year":"2021","journal-title":"JAMA Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"15_suppl.8562","DOI":"10.1200\/jco.2021.39.15_suppl.8562","article-title":"The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1706837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:14:25Z","timestamp":1764652465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1706837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":51,"alternative-id":["10.3389\/fonc.2025.1706837"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1706837","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1706837"}}